Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05411159
Other study ID # 2022020817
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 7, 2022
Est. completion date December 31, 2024

Study information

Verified date September 2022
Source Beijing Chao Yang Hospital
Contact Yan Xiang, M.D.
Phone +8601058231330
Email yanxiang9991@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to verify whether an Opioid-free Anesthesia (OFA) could effectively reduce the incidence of PONV after thoracoscopic-assisted surgery compared with standard general anesthesia (OA) regimens.


Description:

Postoperative Nausea and Vomiting (PONV) is one of the most common complications after general anesthesia, which significantly reduces postoperative comfort and satisfaction of patients perioperatively. Meta-analysis showed that Opioid-free Anesthesia (OFA) significantly reduced the risk of postoperative PONV events in patients undergoing gynecology, breast, and abdominal surgery compared with standard general anesthesia (OA). The main hypothesis of the study is that an OFA could reduce the incidence of PONV in patients after thoracoscopic-assisted surgery than OA.


Recruitment information / eligibility

Status Recruiting
Enrollment 168
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Inpatients planning elective thoracoscopic lobectomy or wedge resection under general anesthesia Exclusion Criteria: - ASA classification > 4 - BMI>35kg/m2 - Unable to communicate before surgery - Received radiation therapy, chemotherapy, opioids or hormonal drugs within 14 days before surgery - Anticipated intolerance to the anesthesia protocol of this study - Expect prolonged mechanical ventilation after surgery - Decline

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Opioid-Free Anesthesia (OFA)
Opioid-free general anesthesia protocol: After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml). Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.). Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h). Flurbiprofen (50 mg i.v.) given at the time of skin suture.
Standard general anesthesia (OA)
Standard general anesthesia protocol: After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.). Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ). Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min). Flurbiprofen (50 mg i.v.) given at the time of skin suture.

Locations

Country Name City State
China Beijing Chaoyang Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Chao Yang Hospital

Country where clinical trial is conducted

China, 

References & Publications (4)

Dell-Kuster S, Gomes NV, Gawria L, Aghlmandi S, Aduse-Poku M, Bissett I, Blanc C, Brandt C, Ten Broek RB, Bruppacher HR, Clancy C, Delrio P, Espin E, Galanos-Demiris K, Gecim IE, Ghaffari S, Gié O, Goebel B, Hahnloser D, Herbst F, Orestis I, Joller S, Kan — View Citation

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. — View Citation

Kleif J, Waage J, Christensen KB, Gögenur I. Systematic review of the QoR-15 score, a patient- reported outcome measure measuring quality of recovery after surgery and anaesthesia. Br J Anaesth. 2018 Jan;120(1):28-36. doi: 10.1016/j.bja.2017.11.013. Epub — View Citation

Myles PS, Wengritzky R. Simplified postoperative nausea and vomiting impact scale for audit and post-discharge review. Br J Anaesth. 2012 Mar;108(3):423-9. doi: 10.1093/bja/aer505. Epub 2012 Jan 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Postoperative length of hospital stay Length of hospital stay in days Up to 7 days after surgery
Other Postoperative anesthesia care unit (PACU) duration PACU duration in minutes Up to 4 hours after surgery
Other Intraoperative complications Assessed according to ClassIntra complication classifications From entering to leaving the operating room, an average of 4 hours
Other Postoperative Complications Assessed according to Clavien-Dindo surgical complication classifications within 7 days after surgery or discharge
Other Health and well-being after surgery Assessed according to the Short-Form (SF-36) health survey, included 36 items groups in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health. 6 month after surgery
Primary Incidence of postoperative nausea and vomiting Assessed using Myles's simplified postoperative nausea and vomiting impact scale.
The scale on the scale is a composite of the following 2 parts:
(1) vomited or had dry-retching (0-3 points), and (2) nausea ( 0-3 points). (High scores represent severe).
The score>0 is regarded as PONV occurred.
24 hours after surgery
Secondary The score of Simplified postoperative nausea and vomiting impact scale Assessed using Myles's simplified postoperative nausea and vomiting impact scale.
The score on the scale is a composite of the following 2 parts:
(1) vomited or had dry-retching score (0-3 points), and (2) nausea ( 0-3 points). (High scores represent severe)
24 hours after surgery
Secondary Quality of post-operative recovery Assessed by the of quality of recovery-15 (QoR-15) scale. (0-150 points, High scores represent better) 24 hours after surgery
Secondary Postoperative pain at rest and cough Assessed by the Numerical Assessment Scale (NRS) for pain. (0-10 points, High scores represent worse) 24 hours after surgery
Secondary The six minute walking test (6MWT) Assessed by the 6MWT worksheet and report. (High scores represent better) 48 hours after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04095624 - Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion N/A
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT04598074 - Opioid Package Prototype (OPP) N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Completed NCT03570320 - Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries? N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Recruiting NCT06055205 - A Pain and Coordination Plan for Reduced Opioid Use After Accidental Injuries N/A
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT04868552 - Naloxone Education in Total Joint Patients N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Terminated NCT06217380 - Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program N/A
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Completed NCT03472521 - Prevention of Persistent Opioid Use in Mothers Phase 4